News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma (64 KB)
25.11.2020
Download
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis (29 KB)
23.11.2020
Download
Enhancing Market Position in the Synthetic Biology Industry to Promote High End Biologically Manufactured Alternatives—A Dialogue with Cathay Biotech Inc. Chairman Liu Xiucai (298 KB)
20.11.2020
Download
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors (24 KB)
16.11.2020
Download
Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics (57 KB)
9.11.2020
Download
Galecto Announces Pricing of Initial Public Offering (58 KB)
29.10.2020
Download
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company (157 KB)
28.10.2020
Download
Dren Bio Announces a $60M Series A Financing (467 KB)
16.10.2020
Download
Cathay Biotech to Invest USD596.5 Million in Northwest China's Largest Synthetic Biology Project (200 KB)
12.10.2020
Download
New CEO Joins Karius to Lead Next Growth Phase (97 KB)
6.10.2020
Download

<123 4 5 6 >

Das Derby der Impfstoffhersteller (163 KB)
16.11.2020
Download Read more
Gewinne aus dem Labor (310 KB)
01.11.2020
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)
18.08.2020
Download Read more
«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)
18.08.2020
Download Read more
Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)
25.07.2020
Download Read more
Virus eröffnet Anlage-Chancen (100 KB)
2.4.2020
Download Read more
Pharmaprofis kaufen keine Corona-Aktien (123 KB)
1.4.2020
Download Read more
Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma (64 KB)

Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis (29 KB)

Enhancing Market Position in the Synthetic Biology Industry to Promote High End Biologically Manufactured Alternatives—A Dialogue with Cathay Biotech Inc. Chairman Liu Xiucai (298 KB)

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors (24 KB)

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics (57 KB)

Galecto Announces Pricing of Initial Public Offering (58 KB)

Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company (157 KB)

Dren Bio Announces a $60M Series A Financing (467 KB)

Cathay Biotech to Invest USD596.5 Million in Northwest China's Largest Synthetic Biology Project (200 KB)

New CEO Joins Karius to Lead Next Growth Phase (97 KB)

Das Derby der Impfstoffhersteller (163 KB)

Gewinne aus dem Labor (310 KB)

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)

«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)

Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)

Virus eröffnet Anlage-Chancen (100 KB)

Pharmaprofis kaufen keine Corona-Aktien (123 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2020 (1299 KB)

Pharma / Biotech M&A Transctions 2005-2019 (119 KB)